George I. Papakostas, MD

Clinical Trials Network and Institute, Department of Psychiatry, Massachusetts General Hospital; and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts

JCP
Overcoming Challenges to Treat Inadequate Response in MDD
DELETE eReport

May 12, 2020

How do you determine if a patient is experiencing nonresponse to an antidepressant? In this activity, experts discuss augmentation and adjunctive treatment strategies, as well as best practices for...
George I. Papakostas, W. Clay Jackson, Roueen Rafeyan, et al
JCP
Use of Measurement-Based Care to Address Inadequate Antidepressant Response
DELETE eReport

May 5, 2020

You may think using rating scales to measure depression symptoms takes too long. But that time may be well spent. In this activity, experts discuss the value of measurement-based...
Madhukar H. Trivedi, George I. Papakostas, W. Clay Jackson, et al
JCP
Recognizing Inadequate Response in Patients With MDD
DELETE eReport

May 5, 2020

Can you recognize inadequate antidepressant response? How does it differ from treatment-resistant depression? In this activity, experts discuss definitions of response as well as residual symptoms seen with inadequate...
W. Clay Jackson, George I. Papakostas, Roueen Rafeyan, et al
JCP
Review Article

February 4, 2020

Ketamine infusion can produce rapid antidepressant effects, but how to maintain these initial treatment gains remains unclear. This article suggests directions for future investigation in light of past attempts...
George I. Papakostas
JCP
Original Research

September 24, 2019

The use of atypical antipsychotics as adjunctive treatment for nonresponsive depression is limited by their side effects. This study explores whether pimavanserin can be both an efficacious and tolerable...
Maurizio Fava, Bryan Dirks, Marlene P. Freeman, et al
JCP
Review Article

June 4, 2019

To optimize treatment choices for patients with treatment-resistant depression (TRD), TRD should be defined accurately and unambiguously. This review examines extant descriptions and staging models of TRD and posits...
Naji C. Salloum, George I. Papakostas
JCP
Original Research

July 25, 2017

Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...
Nadia Iovieno, Richard C. Shelton, Samuel R. Petrie, et al
JCP
Original Research

April 26, 2017

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...
David Mischoulon, Richard C. Shelton, Lee Baer, et al
JCP
Educational Activity

August 24, 2016

George I. Papakostas
JCP
Meta-Analysis

May 25, 2016

Is one drug good enough? Read this review of 215 double-blind, randomized, placebo-controlled trials to discover which monotherapies have overall short-term efficacy in treating MDD and bipolar depression.
George I. Papakostas, Max A. Martinson, Maurizio Fava, et al
JCP
Original Research

May 25, 2016

John M. Zajecka, Maurizio Fava, Richard C. Shelton, et al
JCP
Supplement Article

January 27, 2016

George I. Papakostas

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe